Roschier represents Mobidiag in the sale of the company to Hologic
The shareholders of Mobidiag, a Finnish-French biotechnology company, have agreed to sell the company to US-based medical technology company Hologic, Inc. for an enterprise value of approximately EUR 668 million. Roschier advises Mobidiag and its shareholders in the transaction.
The acquisition is expected to close in the fourth quarter of 2021, subject to receipt of certain required regulatory approvals and other customary closing conditions.
Privately held, commercial-stage Finnish-French developer Mobidiag Oy develops and markets innovative molecular diagnostic solutions for gastrointestinal infections, antimicrobial resistance management, healthcare associated infections, respiratory infections and sepsis. Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.